Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Wu, Jashin J. [2 ]
Reich, Kristian [3 ]
Gooderham, Melinda [4 ,5 ]
Lebwohl, Mark [6 ]
White, Katy [7 ]
Cross, Nancy [8 ]
Cioffi, Christopher [9 ]
Papp, Kim A. [10 ,11 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dermatol Res & Educ Fdn, Irvine, CA USA
[3] Univ Med Ctr Hamburg Eppendorf, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[4] Prob Med Res, SKiN Ctr Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Kingston, ON, Canada
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] UCB Pharma, Slough, Berks, England
[8] UCB Pharma, Brussels, Belgium
[9] UCB Pharma, Raleigh, NC USA
[10] Prob Med Res, Waterloo, ON, Canada
[11] K Papp Clin Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27380
引用
收藏
页码：AB139 / AB139
页数：1
相关论文
共 50 条
  • [1] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [2] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    [J]. LANCET, 2021, 397 (10273): : 475 - 486
  • [3] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
    Strober, Bruce E.
    Pinter, Andreas
    Warren, Richard B.
    Blauvelt, Andrew
    Sebastian, Michael
    De Cuyper, Dirk
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    Gooderham, Melinda
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138
  • [4] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1395 - 1406
  • [5] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gooderham, Melinda
    Papp, Kim A.
    Philipp, Sandra
    Wu, Jashin J.
    Igarashi, Atsuyuki
    Flack, Mary
    Geng, Ziqian
    Wu, Tianshuang
    Camez, Anne
    Williams, David
    Langley, Richard G.
    [J]. JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658
  • [6] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    [J]. JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [7] BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIES
    Gottlieb, Alice B.
    Augustin, Matthias
    Lambert, Jo
    Pinter, Andreas
    Savage, Laura J.
    Tsai, Tsen-Fang
    Foley, Peter
    Paul, Carle
    Warham, Rhys
    Lambert, Jeremy
    Wiegratz, Susanne
    Stahle, Mona
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [8] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    [J]. JOURNAL OF DERMATOLOGY, 2024,
  • [9] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)
    Gordon, K. B.
    Foley, P.
    Krueger, J. G.
    [J]. LANCET, 2021, 397 (10280): : 1182 - 1182
  • [10] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
12345